BioNTech SE/$BNTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
- Ticker
- $BNTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,807
- Headquarters
- Mainz, Germany
- Website
- www.biontech.de
BioNTech SE Metrics
BasicAdvanced
$22B
-
-$7.59
1.29
-
Price and volume
Market cap
$22B
Beta
1.29
52-week high
$124.00
52-week low
$79.52
Average daily volume
1M
Financial strength
Current ratio
7.848
Quick ratio
7.033
Long term debt to equity
0.015
Total debt to equity
0.018
Interest coverage (TTM)
-127.06%
Profitability
EBITDA (TTM)
-1,540.904
Gross margin (TTM)
76.62%
Net profit margin (TTM)
-63.64%
Operating margin (TTM)
-68.57%
Effective tax rate (TTM)
-3.49%
Revenue per employee (TTM)
$379,420
Management effectiveness
Return on assets (TTM)
-5.41%
Return on equity (TTM)
-9.30%
Valuation
Price to revenue (TTM)
7.39
Price to book
1.25
Price to tangible book (TTM)
1.39
Price to free cash flow (TTM)
44.04
Free cash flow yield (TTM)
2.27%
Free cash flow per share (TTM)
2.002
Growth
Revenue change (TTM)
-7.93%
Earnings per share change (TTM)
374.01%
3-year revenue growth (CAGR)
-33.92%
3-year earnings per share growth (CAGR)
-27.80%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
Analyst projections of the future price of BioNTech SE stock.
Bulls say / Bears say
Gotistobart produced a promising survival signal in a small randomised stage-one comparison: median overall survival was 18.5 months versus 10.0 months with docetaxel. The pivotal stage-two part of the trial is still under way. (BioNTech)
Pumitamig showed encouraging early activity with chemotherapy in advanced lung cancer, including confirmed response rates of 57.1% in non-squamous and 68.4% in squamous disease. The results support further testing, though the global study is still progressing through Phase 3. (BioNTech)
BioNTech’s HER2-targeted antibody-drug conjugate trastuzumab pamirtecan achieved a 49.3% confirmed response rate in a Phase 2 endometrial-cancer cohort. A global confirmatory Phase 3 trial is under way, offering another potential route to oncology growth beyond lung cancer. (BioSpace)
COVID-19 vaccine demand is weakening: BioNTech cut its 2026 revenue forecast to €1.6–1.9 billion from €2.0–2.3 billion, citing softer demand and the use of existing German vaccine stocks. That leaves near-term revenue exposed while oncology products remain in development. (BioNTech)
The company is spending heavily before its oncology pipeline has produced a commercial product: it reported a €1.35 billion net loss for the first half of 2026, alongside more than €1.1 billion of R&D expense. Its substantial cash reserves provide a buffer, but do not remove the risk that losses persist. (StockTitan)
BioNTech and Genentech stopped a Phase 2 colorectal-cancer trial of their personalised mRNA therapy after an independent monitoring board found a numerical imbalance in overall survival and judged further testing unlikely to change the outcome. The setback raises questions about the approach in this setting, although a separate combination study in pancreatic cancer continues. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioNTech SE News
AllArticlesVideos
Funds containing BioNTech SE
Fund name | Fund size | $BNTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.66% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.66% |
iShares Dow Jones Global Leaders Screened$IGSU | $2.3B | 0.04% |
iShares Dow Jones Global Leaders Screened£IGSG | $2.3B | 0.04% |
L&G Global Equity£LGGG | $2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.